Goldman Sachs Group Inc Adicet Bio, Inc. Transaction History

Goldman Sachs Group Inc

  • $596 Billion
  • Q1 2025

A detailed history of Goldman Sachs Group Inc transactions in Adicet Bio, Inc. stock. As of the latest transaction made, Goldman Sachs Group Inc holds 3,816,556 shares of ACET stock, worth $2.75 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
3,816,556
Previous 3,816,556 -0.0%
Holding current value
$2.75 Million
Previous $2.9 Million -0.0%
% of portfolio
0.0%
Previous 0.0%

Shares

21 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2025

May 09, 2025
BUY
$0.76 - $1.09 $48,405 - $69,423
63,691 Added 1.7%
3,816,556 $2.9 Million
Q4 2024

Feb 11, 2025
SELL
$0.86 - $1.52 $6,133 - $10,840
-7,132 Reduced 0.19%
3,752,865 $3.6 Million
Q3 2024

Nov 14, 2024
SELL
$1.07 - $1.63 $560,011 - $853,101
-523,375 Reduced 12.22%
3,759,997 $5.41 Million
Q2 2024

Aug 13, 2024
BUY
$1.21 - $2.4 $336,119 - $666,684
277,785 Added 6.93%
4,283,372 $5.18 Million
Q1 2024

May 15, 2024
BUY
$1.76 - $3.45 $7 Million - $13.7 Million
3,976,974 Added 13899.19%
4,005,587 $9.41 Million
Q4 2023

Feb 13, 2024
SELL
$1.11 - $1.89 $34,296 - $58,397
-30,898 Reduced 51.92%
28,613 $54,000
Q3 2023

May 14, 2024
BUY
$1.37 - $3.4 $42,330 - $105,053
30,898 Added 107.99%
59,511 $81,000
Q3 2023

Nov 14, 2023
SELL
$1.37 - $3.4 $14,354 - $35,625
-10,478 Reduced 14.97%
59,511 $81,000
Q2 2023

May 14, 2024
SELL
$2.13 - $7.13 $62,445 - $209,030
-29,317 Reduced 29.52%
69,989 $170,000
Q2 2023

Aug 14, 2023
SELL
$2.13 - $7.13 $62,445 - $209,030
-29,317 Reduced 29.52%
69,989 $170,000
Q1 2023

May 14, 2024
SELL
$5.52 - $9.23 $1.04 Million - $1.74 Million
-188,921 Reduced 65.55%
99,306 $572,000
Q1 2023

May 11, 2023
SELL
$5.52 - $9.23 $1.04 Million - $1.74 Million
-188,921 Reduced 65.55%
99,306 $572,000
Q4 2022

May 14, 2024
SELL
$7.72 - $21.27 $824,912 - $2.27 Million
-106,854 Reduced 27.05%
288,227 $2.58 Million
Q4 2022

Feb 13, 2023
SELL
$7.72 - $21.27 $824,912 - $2.27 Million
-106,854 Reduced 27.05%
288,227 $2.58 Million
Q3 2022

May 14, 2024
BUY
$13.43 - $18.74 $665,241 - $928,267
49,534 Added 14.33%
395,081 $5.62 Million
Q3 2022

Nov 10, 2022
BUY
$13.43 - $18.74 $665,241 - $928,267
49,534 Added 14.33%
395,081 $5.62 Million
Q2 2022

May 14, 2024
BUY
$10.26 - $20.81 $3.25 Million - $6.6 Million
316,934 Added 1107.66%
345,547 $5.05 Million
Q2 2022

Aug 15, 2022
BUY
$10.26 - $20.81 $1.21 Million - $2.45 Million
117,516 Added 51.54%
345,547 $5.05 Million
Q1 2022

May 16, 2022
BUY
$11.53 - $19.97 $742,601 - $1.29 Million
64,406 Added 39.36%
228,031 $4.55 Million
Q4 2021

Feb 14, 2022
BUY
$7.37 - $17.49 $925,738 - $2.2 Million
125,609 Added 330.41%
163,625 $2.86 Million
Q3 2021

Nov 10, 2021
BUY
$6.29 - $9.93 $239,120 - $377,498
38,016 New
38,016 $298,000

Others Institutions Holding ACET

# of Institutions
63
Shares Held
57.5M
Call Options Held
36.9K
Put Options Held
16.5K
View Full List

About Adicet Bio, Inc.

ACET Quotes by TradingView
  • Ticker ACET
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,030,800
  • Market Cap $28.8M
  • Description
  • Adicet Bio, Inc., a biotechnology company, discovers and develops allogeneic gamma delta T cell therapies for cancer and other diseases. The company offers gamma delta T cells engineered with chimeric antigen receptors and T cell receptor-like antibodies to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune respo...
More about ACET
Track This Portfolio

Track Goldman Sachs Group Inc Portfolio

Follow Goldman Sachs Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Goldman Sachs Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Goldman Sachs Group Inc with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email